Medtronic (NYSE:MDT) Stock Unloaded Rep. Julie Johnson

by · The Markets Daily

Representative Julie Johnson (D-Texas) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Medtronic Stock Down 2.2%

Shares of Medtronic stock traded down $2.18 during trading on Friday, hitting $96.82. 9,034,766 shares of the stock traded hands, compared to its average volume of 5,557,880. The stock has a market cap of $124.12 billion, a P/E ratio of 26.10, a PEG ratio of 2.55 and a beta of 0.71. The company has a fifty day moving average price of $98.99 and a two-hundred day moving average price of $94.88. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the business posted $1.26 EPS. Medtronic’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada lifted their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Truist Financial cut their price objective on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Sanford C. Bernstein raised their target price on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.28.

View Our Latest Analysis on MDT

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Delos Wealth Advisors LLC purchased a new stake in Medtronic in the 2nd quarter worth approximately $27,000. Corundum Trust Company INC purchased a new position in Medtronic during the 3rd quarter valued at about $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic in the fourth quarter valued at $27,000. Valley Wealth Managers Inc. bought a new position in Medtronic in the third quarter worth about $29,000. Finally, Board of the Pension Protection Fund purchased a new stake in Medtronic in the fourth quarter worth $29,000. 82.06% of the stock is owned by institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Further Reading